AMAG Pharmaceuticals

AMAG is a biopharmaceutical company focused on bringing therapeutics to market that provide clear benefits and help improve people’s lives. Its products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR, the Company also helps families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.

Company Growth (employees)
Waltham, US
Size (employees)
545 (est)
AMAG Pharmaceuticals was founded in 1981 and is headquartered in Waltham, US

AMAG Pharmaceuticals Office Locations

AMAG Pharmaceuticals has offices in Waltham, Tucson and San Bruno
Waltham, US (HQ)
1100 Winter St
San Bruno, US
1200 Bayhill Dr
Tucson, US
6550 S Bay Colony Dr
Show all (3)

AMAG Pharmaceuticals Financials and Metrics

AMAG Pharmaceuticals Financials

AMAG Pharmaceuticals's revenue was reported to be $532.1 m in FY, 2016

Revenue (Q2, 2017)

158.4 m

Gross profit (Q2, 2017)

152.8 m

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

(14.1 m)

EBIT (Q2, 2017)

3.6 m

Market capitalization (16-Feb-2018)

653.3 m

Cash (30-Jun-2017)

260.1 m
AMAG Pharmaceuticals's current market capitalization is $653.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


80.9 m124.4 m418.3 m532.1 m

Revenue growth, %


Cost of goods sold

12 m20.3 m10 m20.6 m

Gross profit

68.9 m104.1 m408.3 m511.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


21.6 m20.8 m24.8 m25.5 m89.5 m123.9 m96.2 m109.3 m127.4 m143.8 m139 b158.4 m

Cost of goods sold

2.5 m2.8 m2.7 m3 m21 m19.7 m3.3 m5.5 m5.2 m5 m5 b5.6 m

Gross profit

19.1 m18 m22.1 m22.5 m68.5 m104.2 m92.9 m103.8 m122.2 m138.8 m134 b152.8 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


27 m119.3 m228.7 m274.3 m

Accounts Receivable

6.8 m38.2 m85.7 m92.4 m


17.2 m40.6 m40.6 m37.3 m

Current Assets

244.4 m274 m606.7 m718.6 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


30.9 m200.9 m202.1 m196.2 m243.8 m89.9 m167.5 m203.4 m251.1 m305.3 m252.9 m260.1 m

Accounts Receivable

8.8 m10.1 m10.6 m10.9 m56.2 m58 m73.7 m82.8 m66.1 m70.1 m85.2 m89.5 m


14.7 m20.8 m22 m19.6 m35.9 m34.4 m37.2 m42 m39.6 m38.2 m36.9 m37.5 m

Current Assets

245.6 m421 m424.1 m427 m519.5 m555.5 m655.4 m622.2 m665.6 m736.8 m688.9 m537.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(9.6 m)135.8 m32.8 m(2.5 m)

Depreciation and Amortization

3.1 m7 m69.1 m99.9 m

Accounts Receivable

(432 k)3.6 m(37 m)(9.9 m)


(1 m)(1.4 m)(5.2 m)(2.4 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(145 k)(7.1 m)(1.5 m)1.5 m12.9 m33.3 m(20.6 m)(7.5 m)(596 k)16.2 m(36.6 b)

Depreciation and Amortization

19.6 m

Accounts Receivable

10.6 m10.9 m56.2 m58 m73.7 m2.9 m66.1 m70.1 m85.2 m


22 m19.6 m35.9 m34.4 m37.2 m(2.2 m)39.6 m38.2 m36.9 m
Y, 2017

Financial Leverage

2.4 x
Show all financial metrics

AMAG Pharmaceuticals Market Value History

AMAG Pharmaceuticals's Web-traffic and Trends

AMAG Pharmaceuticals Company Life and Culture

You may also be interested in